LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 268

Search options

  1. Book ; Online ; E-Book: Dermatologic reactions to cancer therapies

    Fabbrocini, Gabriella / Lacouture, Mario E. / Tosti, Antonella

    (Series in dermatological treatment)

    2019  

    Author's details edited by Gabriella Fabbrocini, Mario E. Lacouture, Antonella Tosti
    Series title Series in dermatological treatment
    Keywords Skin/Diseases/Treatment ; Skin/Cancer/Treatment ; Skin/Effect of drugs on ; Dermatology ; Oncology
    Subject code 616.99477
    Language English
    Size 1 Online-Ressource (viii, 173 Seiten), Illustrationen
    Publisher CRC Press
    Publishing place Boca Raton
    Publishing country United States
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT020046982
    ISBN 978-1-351-97284-0 ; 9781138633254 ; 9781138035539 ; 1-351-97284-7 ; 1138633259 ; 113803553X
    DOI 10.1201/9781315267364
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Book: Dermatologic principles and practice in oncology

    Lacouture, Mario E.

    conditions of the skin, hair, and nails in cancer patients

    2014  

    Abstract: This is the first book to focus on frequent and frequently disabling side effects involving the skin, hair, and nails in cancer patients. It provides detailed descriptions of mechanism-of-action in all current oncology drugs and the clinical ... ...

    Author's details ed. by Mario E. Lacouture
    Abstract "This is the first book to focus on frequent and frequently disabling side effects involving the skin, hair, and nails in cancer patients. It provides detailed descriptions of mechanism-of-action in all current oncology drugs and the clinical presentation and mechanisms underlying their dermatologic side effects, alongside carefully presented treatment recommendations, allowing physicians to significantly enhance their care of patients with cancer. Whereas existing oncology and dermatology textbooks only briefly deal with this topic, this resource offers dermatologists and other practitioners a focused perspective on cancer-related skin conditions"--Provided by publisher
    Keywords Skin Diseases / etiology ; Skin Diseases / psychology ; Neoplasms / complications ; Antineoplastic Agents / adverse effects ; Skin Manifestations ; Skin Care / nursing
    Language English
    Size X, 430 S. : Ill., graph. Darst.
    Publisher Wiley-Blackwell
    Publishing place Hoboken, NJ
    Publishing country Great Britain
    Document type Book
    Note Includes bibliographical references and index
    HBZ-ID HT017800108
    ISBN 978-0-470-62188-2 ; 9781118590607 ; 9781118590614 ; 9781118590621 ; 9781118590638 ; 0-470-62188-5 ; 1118590600 ; 1118590619 ; 1118590627 ; 1118590635
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Book: Characterization and management of dermatologic adverse events with the NovoTTF-100A System

    Lacouture, Mario E.

    a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma

    (Seminars in oncology ; 41,3, Suppl. 4)

    2014  

    Author's details Mario E. Lacouture
    Series title Seminars in oncology ; 41,3, Suppl. 4
    Collection
    Language English
    Size S14 S. : Ill.
    Publisher Saunders
    Publishing place Philadelphia, Pa
    Publishing country United States
    Document type Book
    HBZ-ID HT018400605
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  4. Article ; Online: Dermatologic immune-related adverse events to checkpoint inhibitors in cancer.

    Shah, Neil J / Lacouture, Mario E

    The Journal of allergy and clinical immunology

    2022  Volume 151, Issue 2, Page(s) 407–409

    MeSH term(s) Humans ; Neoplasms/drug therapy ; Immune System Diseases
    Language English
    Publishing date 2022-12-02
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 121011-7
    ISSN 1097-6825 ; 1085-8725 ; 0091-6749
    ISSN (online) 1097-6825 ; 1085-8725
    ISSN 0091-6749
    DOI 10.1016/j.jaci.2022.11.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Book: Dermatologic toxicities associated with EGFR inhibitor therapies

    Lacouture, Mario E.

    (Oncology ; 21,11, Suppl. 5)

    2007  

    Title variant Dermatologic toxicities associated with EGFR-inhibitor therapies
    Author's details guest ed. Mario E. Lacouture
    Series title Oncology ; 21,11, Suppl. 5
    Collection
    Language English
    Size 36 S. : Ill., graph. Darst.
    Publisher PRR
    Publishing place Melville, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT015351580
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  6. Article ; Online: In Reply.

    Lacouture, Mario E / Patel, Anisha B / Rosenberg, Jonathan E / O'Donnell, Peter H

    The oncologist

    2022  Volume 27, Issue 10, Page(s) e827–e828

    MeSH term(s) Antibodies, Monoclonal ; Humans ; Immunoconjugates ; Nectins
    Chemical Substances Antibodies, Monoclonal ; Immunoconjugates ; Nectins ; enfortumab vedotin (DLE8519RWM)
    Language English
    Publishing date 2022-08-29
    Publishing country England
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1093/oncolo/oyac171
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Management of dermatologic toxicities.

    Lacouture, Mario E

    Journal of the National Comprehensive Cancer Network : JNCCN

    2015  Volume 13, Issue 5 Suppl, Page(s) 686–689

    Abstract: ... patients on optimal drugs and doses. At the NCCN 20th Annual Conference, Dr. Mario E. Lacouture advised ...

    Abstract Dermatologic toxicities related to cancer therapies have become even more common with the use of targeted treatments. A proactive approach is necessary to reduce the pain and suffering these patients experience. The oncologist should become comfortable in preventing and managing these complications to keep patients on optimal drugs and doses. At the NCCN 20th Annual Conference, Dr. Mario E. Lacouture advised clinicians on appropriate strategies to manage rash, paronychia, alopecia, and other dermatologic conditions frequently seen in patients with cancer.
    MeSH term(s) Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Disease Management ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Humans ; Neoplasms/drug therapy ; Skin Diseases/chemically induced ; Skin Diseases/prevention & control
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2015-05-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2015.0204
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.

    Lacouture, Mario E / Patel, Anisha B / Rosenberg, Jonathan E / O'Donnell, Peter H

    The oncologist

    2022  Volume 27, Issue 3, Page(s) e223–e232

    Abstract: Enfortumab vedotin is a first-in-class Nectin-4-directed antibody-drug conjugate approved by the US Food and Drug Administration for the treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC) previously treated with a ... ...

    Abstract Enfortumab vedotin is a first-in-class Nectin-4-directed antibody-drug conjugate approved by the US Food and Drug Administration for the treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC) previously treated with a platinum-based chemotherapy and a programmed death receptor-1/programmed death-ligand 1 (PD-1/L1) inhibitor, or patients with la/mUC who are ineligible for cisplatin-based chemotherapy and have previously received one or more prior lines of therapy. Enfortumab vedotin is the only drug to have demonstrated survival benefit versus chemotherapy in a randomized controlled trial in patients with la/mUC previously treated with platinum-based chemotherapy and a PD-1/L1 inhibitor. The development of dermatologic events following the administration of enfortumab vedotin is anticipated given the expression of Nectin-4 in epidermal keratinocytes and skin appendages (eg, sweat glands and hair follicles). There is the potential for rare but severe and possibly fatal cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrosis, as described in the boxed warning of the US prescribing information for enfortumab vedotin. This manuscript describes the presumed pathophysiology and manifestations of dermatologic reactions related to enfortumab vedotin, and presents recommendations for prevention and treatment, to provide oncologists and other healthcare providers with an awareness of these potential adverse events to best anticipate and manage them.
    MeSH term(s) Antibodies, Monoclonal ; Carcinoma, Transitional Cell/drug therapy ; Cell Adhesion Molecules/metabolism ; Cell Adhesion Molecules/therapeutic use ; Female ; Humans ; Immunoconjugates/adverse effects ; Male ; Nectins ; Platinum/therapeutic use ; Programmed Cell Death 1 Receptor/therapeutic use ; Urologic Neoplasms/drug therapy
    Chemical Substances Antibodies, Monoclonal ; Cell Adhesion Molecules ; Immunoconjugates ; Nectins ; Programmed Cell Death 1 Receptor ; Platinum (49DFR088MY) ; enfortumab vedotin (DLE8519RWM)
    Language English
    Publishing date 2022-03-09
    Publishing country England
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1093/oncolo/oyac001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Management of Dermatologic Toxicities Associated With Targeted Therapy.

    Lacouture, Mario E

    Journal of the advanced practitioner in oncology

    2016  Volume 7, Issue 3, Page(s) 331–334

    Language English
    Publishing date 2016-04-01
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2150-0878
    ISSN 2150-0878
    DOI 10.6004/jadpro.2016.7.3.18
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer.

    Lacouture, Mario E / Goldfarb, Shari B / Markova, Alina / Chawla, Sant P / Dewnani, Karan / Iacobucci, Marc / Lang, Julie E

    Breast cancer research and treatment

    2022  Volume 194, Issue 1, Page(s) 57–64

    MeSH term(s) Breast Neoplasms/pathology ; Female ; Humans ; Paclitaxel/adverse effects ; Progression-Free Survival ; Skin Neoplasms/drug therapy ; Skin Neoplasms/secondary ; Treatment Outcome
    Chemical Substances Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2022-04-26
    Publishing country Netherlands
    Document type Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article
    ZDB-ID 604563-7
    ISSN 1573-7217 ; 0167-6806
    ISSN (online) 1573-7217
    ISSN 0167-6806
    DOI 10.1007/s10549-022-06584-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top